China's Medical Technology Firm Genesis MedTech Receives NMPA Approval for Aortic Leak Solution in 2025
The J-VALVE® Transfemoral Transcatheter Aortic Valve Replacement (TAVR) System (J-VALVE TF) has made a significant breakthrough in the treatment of aortic regurgitation, a progressive and potentially life-threatening condition that is undertreated despite being one of the more common valvular heart diseases worldwide.
This innovative system, developed by Genesis MedTech, has received approval from China's National Medical Products Administration (NMPA) for the treatment of aortic regurgitation. Warren Wang, Chairman and CEO of Genesis MedTech, stated that J-VALVE TF provides a safer and faster path to recovery.
The J-VALVE TF's patented anchoring design enhances safety by ensuring secure valve placement, protecting coronary flow, and reducing the risk of complications such as paravalvular leak and conduction block. This design has demonstrated improvements in cardiac function and hemodynamic performance.
One of the most promising aspects of the J-VALVE TF is its minimally invasive approach. Unlike open-heart surgery, the J-VALVE TF offers an alternative by using a transfemoral approach, significantly reducing surgical trauma and procedural risk. This means most patients can walk the day after treatment.
The J-VALVE TF has also shown impressive results in avoiding third-degree atrioventricular block, with a 94.5% success rate. The 12-month follow-up results on J-VALVE TF showed a 3.2% all-cause mortality rate, offering hope to patients with severe aortic regurgitation who previously had few safe options.
Professor Wei Lai from Zhongshan Hospital, Fudan University, presented these promising results at EuroPCR 2024, emphasising the potential of the J-VALVE TF in transforming the treatment landscape for aortic regurgitation patients.
With its innovative design, minimally invasive approach, and promising results, the J-VALVE TF is poised to become a game-changer in the treatment of aortic regurgitation, offering a brighter future for those affected by this condition.
